The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: Current practice and future trends

American Journal of Cardiology

Volumn 85, Issue 8 SUPPL. 1, 2000, Pages 32-38

  Campbell, Kevin R ^a   Ohman, E Magnus ^a   Cantor, Warren ^a   Lincoff, A Michael ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LAMIFIBAN; RECOMBINANT PLASMINOGEN ACTIVATOR; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG UTILIZATION; HEART MUSCLE REPERFUSION; HUMAN; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 0034720137     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00877-8     Document Type: Article

References (27)

1. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indication for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-322.
4. The GUSTO-IIb Angioplasty Substudy Investigators. An international randomized trial of 1138 patients comparing primary coronary angioplasty versus tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-1628.
5. Ellis S.G., Topol E.J., Gallison L., Grines C.L., Langburd A.B., Bates E.R., Walton J.A. Jr, O'Neill W.W. Predictors of success for coronary angioplasty performed for acute myocardial infarction. J Am Coll Cardiol. 12:1998;1407-1415.
6. Fuster V., Badimon L., Badimon J.J., Cheseboro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med. 326:1992;310-318.
7. Coller B.S. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med. 43:1992;171-180.
8. Willerson J.T., Golino P., Eidt J., Campbell W.B., Buja L.M. Specific platelet mediators and unstable coronary artery lesions. Circulation. 80:1989;198-205.
9. Gold H.K., Garabedian H.D., Dinsmore R.E., Guerrero L.J., Cigarroa J.E., Palacios I.F., Leinbach R.C. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators observations in animals and humans . Circulation. 95:1997;1755-1759.
10. van den Merkhof L.F., Zijlstra F., Olsson H., Grip L., Veen G., Bar F.W., van den Brand M.J., Simoons M.L., Verheugt F.W. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 33:1999;1528-1532.
11. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM, Sherer J, Van de Werf F, Braunwald E, for the TIMI 14 Investigators. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results from the TIMI 14 trial (abstract). J Am Coll Cardiol 1998;31:191A.
12. Ohman E.M., Lincoff A.M., Bode C., Bachinsky W.B., Ardissimo D., Matteo P.S., Betriu A., Schildcrout J.S., Sketch M., Topol E.J. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction preliminary results form the GUSTO-4 Pilot (SPEED) dose-ranging trial . Circulation. 98:(suppl I):1998;504.
13. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, AndersonK, Van de Werf F, Braunwald E, for the TIMI 14 investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999;99:2720-2732.
14. Ohman EM. SPEED. Presented at the 48th Annual Scientific Sessions of the American College of Cardiology: March 7-10, 1999, New Orleans, LA.
15. Gold H.K., Coller B.S., Yasuda T., Saito T., Fallon J.T., Guerrero J.L., Leinbach R.C., Ziskind A.A., Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 77:1998;670-677.
16. Yasuda T., Gold H.K., Leinbach R.C., Yaoita H., Fallon J.T., Guerrero L., Napier M.A., Bunting S., Collen D. Kistrin, a polypeptide platelet GP IIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activatior in a canine preparation. Circulation. 83:1991;1038-1047.
17. Kleiman N.S., Ohman E.M., Califf R.M., George B.S., Kereiakes D., Aguirre F.V., Weisman H., Schaible T., Topol E.J. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy results of the TAMI-8 pilot study . J Am Coll Cardiol. 22:1993;381-389.
18. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
19. Ronner E, van Kesteren HAM, Zijnen P, Tebbe U, Molhoek P, Cuffie C, Veltri E, Lorenz T, Neuhaus K, Simoons ML. Combined therapy with streptokinase and Integrelin (abstract). J Am Coll Cardiol 1998;31:-191A.
20. The PARADIGM investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Cardiol 1998;32:2003-2010.
21. Collins R., Peto R., Baigent C., Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 336:1997;847-860.
22. Topol E.J. Toward a new frontier in myocardial reperfusion therapy emerging platelet preeminence . Circulation. 97:1998;211-218.
23. Herrmann HC, Moliterno DJ, Bode C, Betriu A, Lincoff AM, Ohman EM. Combination abciximab and reduced-dose reteplase facilitates early PCI in acute MI: results from the SPEED trial. Circulation 1999;100(suppl 1):I-188.
24. Greenbaum AB, Harrington RA, Ohman EM. The use of glycoprotein IIb/IIIa inhibition in acute myocardial infarction. In: Lincoff AM, Topol EJ, eds. Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa in Cardiovascular Disease. Philadelphia: Williams & Wilkins, 1999:229-249.
25. Cigarroa JE, Ferrel MA, Collen DJ, Leinbach RC. Enhanced endogenouscoronary thrombolysis during acute myocardial infarction following selective platelet receptor blockade with ReoPro (abstract). Circulation 1996;94:I-553.
26. Gold HK, Kereiakes DJ, Dinsmore RE, Martin LH, Lausten D, Broderick TM, Anderson KM, Garabedian HD, Leinbach RC. A randomized, placebo-controlled crossover trial of Reopro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: preliminary results (abstract). Circulation 1997;96:I-473.
27. Makkar R, Eigler N, Goff B, Fry E, Barr L, D'Haem C, Fischell T, Litvack F. Primary reperfusion in acute myocardial infarction with reopro and heparin: interim results of ReoMI pilot study (abstract). J Am Coll Cardiol 1998;31:94-A.